<DOC>
	<DOCNO>NCT02876328</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity three vaccine strategy may prevent Ebola virus disease ( EVD ) event child adult . Participants receive either Ad26.ZEBOV ( rHAd26 ) vaccine MVA-BN-Filo ( MVA ) boost , rVSVΔG-ZEBOV-GP ( rVSV ) vaccine without boost , placebo .</brief_summary>
	<brief_title>Partnership Research Ebola VACcinations</brief_title>
	<detailed_description>The purpose study evaluate safety immunogenicity two Ebola virus disease ( EVD ) vaccine , Ad26.ZEBOV ( rHAd26 ) rVSVΔG-ZEBOV-GP ( rVSV ) , child adult . These vaccine study use three different strategy : rHAd26 vaccine plus MVA-BN-Filo ( MVA ) boost , rVSV vaccine without boost . During initial phase study , people older 12 year age enrol . At Day 0 ( study entry ) , participant randomly assign receive Ad26.ZEBOV vaccine placebo . At Day 56 , participant receive Ad26.ZEBOV vaccine receive MVA boost participant receive placebo receive placebo . When additional safety data current lot rVSV vaccine become available ongoing trial United States , new lot rVSV vaccine become available , trial expand include rVSV vaccine strategy match placebo . Once occur , people 1 year age old randomize five group : two group describe , rVSV vaccine without boost , second placebo group . At Day 56 , participant receive rVSV vaccine receive either rVSV boost placebo participant receive placebo receive placebo . Additional study visit occur Days 7 , 14 , 28 , 63 , Months 3 , 6 , 12 . Study follow-up may continue 5 year . Study visit may include blood collection assessment . Some participant may take part substudies , include blood saliva collection .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Informed consent/assent Age great equal 1 year ( initial phase , include rHAd26/MVABNFilo strategy match placebo , age &gt; 12 year enrol ) Planned residency area study site next 12 month Willingness comply protocol requirement Fever great 38º Celsius History EVD ( selfreport ) Pregnancy ( negative urine pregnancy test require female childbearing potential , i.e. , female experience menarche age 14 year old ) Positive HIV test participant less 18 year age Reported current breastfeeding Prior vaccination Ebola ( selfreport ) Any vaccination past 28 day plan within 28 day randomization ( initial vaccination ) In judgement clinician , clinically significant acute/chronic condition would limit ability participant meet requirement study protocol</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ebola Vaccine</keyword>
</DOC>